The Global Uveitis Treatment Market, by Treatment (Corticosteroids, Immunosuppressant, Monoclonal Antibodies, Cycloplegic Agents, Antibiotics, Antivirals, Antifungals, and Analgesics), by Disease Type (Anterior Uveitis, Posterior Uveitis, Intermediate Uveitis, and Panuveitis), by Cause (Infectious Uveitis and Non-infectious Uveitis) and by Region (North America, Latin America, Europe, Asia Pacific, the Middle East, and Africa) was valued at US$ 555.51 million in 2016 and is projected to exhibit a CAGR of 6.0% over the forecast period (2017–2025). 

Surge in incidence of autoimmune disease is expected to be a factor for increasing demand for uveitis treatment. Corticosteroids are emerging as a potential option for the treatment of uveitis and is expected to propel growth of the global uveitis treatment market. According to a study published in the Journal of Ophthalmology in 2014, it was observed that 88% of the patients suffering with Uveitis can be cured with the help of sustained-release intraocular corticosteroids.

According to the Clinical Investigation Department of the Open Access Journals, 2013, number of research studies on various new treatments by companies and research institutes for treatment of uveitis is increasing, which is known to be one of the leading cause of blindness in the U.S. Treatments such as next-generation calcineurin inhibitors that inhibits T-cell proliferation are also being studied for potential treatment for uveitis. Furthermore, a number of innovations in treatment of uveitis were reported in 2015–2017, through FDA approvals. For instance, AbbVie Pharmaceutical Company’s HUMIRA (adalimumab) received U.S. FDA approval in June 2016, which is the first and only FDA-approved non-corticosteroid therapy for non-infectious intermediate, posterior and Panuveitis. Among disease types, the anterior uveitis treatment segment is expected to witness significant traction over the forecast years owing to increasing prevalence of chronic diseases such as eye trauma, mumps and rubella. Moreover, anterior uveitis is the most commonly encountered type of uveitis among the other types and is another factor driving growth of the segment.

Browse 35 Market Data Tables and 30 Figures spread through 170 Pages and in-depth TOC on “Uveitis Treatment Market”- Global Forecast to 2025.

To know the latest trends and insights prevalent in the Uveitis Treatment Market, click the link below:

North America is expected to be the dominant region in the global uveitis treatment market over the forecast period. This is attributed to a large number of regional companies having their uveitis treatment drugs in pipeline. For instance, the EGP-437 developed by Eyegate Pharmaceuticals for the treatment of anterior uveitis is now in Phase III studies of clinical trials and is expected to complete their clinical trials by February, 2018. Various other factors contributing for growth of the market in North America are increasing prevalence of uveitis, rising aging population, and growing companies and government initiatives to reduce diseases associated with eyes. For instance, a Foundation Fighting Blindness partnered by Genentech — a member of Roche Group — Regeneron and The Allergen Foundation started a campaign in 2014 — Envision 20/20. This campaign was started in order to end blindness and raise funds necessary for current and future research to develop treatments for eye diseases. It raised over US$ 111 Million for retinal disease research till June 2016. Asia Pacific market is expected to witness significant growth over the forecast period and this can be attributed towards rise in incidence of chronic diseases as well as increasing local companies investing on development of novel biologics for the treatment of uveitis.

Key Takeaways of the Uveitis Treatment Market:

  • The global uveitis treatment market is expected to exhibit a CAGR of 6.0% over the forecast period, owing to development of innovative uveitis drugs in the established markets in North America and Europe and emerging market in Asia Pacific
  • Among treatments, monoclonal antibodies segment is expected to gain significant traction over the forecast period owing to high efficacy of these drugs for the treatment of uveitis. However, corticosteroids is the most promising treatment in the current market scenario due to its success rate.
  • Among disease types, anterior uveitis is expected to hold a dominant position in the market as it is the most commonly occurring disease type as compared to the other disease types.
  • Some major players operating in the global uveitis treatment market are AbbVie, Inc., Novartis AG, Eyegate Pharmaceuticals, Inc., Santen Pharmaceuticals, Allergan Plc, Regeneron Pharmaceuticals, Inc., Valeant Pharmaceuticals International, Inc., and Alimera Sciences.
Existing Clientele

Joining thousands of companies around the world committed to making the Excellent Business Solutions.

View All Our Clients

Our Trusted Patner